Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cel-Sci Corporation Common Stock (NY:CVM)

8.200 +1.350 (+19.71%)
Official Closing Price Updated: 8:00 PM EDT, Jul 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cel-Sci Corporation Common Stock

< Previous 1 2 3 4 Next >
CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules
From CEL-SCI Corporation
Via Business Wire
CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer
From CEL-SCI Corporation
Via Business Wire
FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Announces Closing of Public Offering
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Announces Pricing of Public Offering
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Announces Proposed Public Offering
From CEL-SCI Corporation
Via Business Wire
CEL-SCI’s Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Announces Combination of Common Stock
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results
From CEL-SCI Corporation
Via Business Wire
CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market
From CEL-SCI Corporation
Via Business Wire
New Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI’s Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Announces Closing of $2.5 Million Offering
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Announces Pricing of $2.5 Million Offering
From CEL-SCI Corporation
Via Business Wire
CEL-SCI’s Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine
From CEL-SCI Corporation
Via Business Wire
Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI’s Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression
From CEL-SCI Corporation
Via Business Wire
CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Announces Closing of $5 Million Offering
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Announces Pricing of $5 Million Public Offering
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Announces Proposed Public Offering of Common Stock
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study
From CEL-SCI Corporation
Via Business Wire
U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025
From CEL-SCI Corporation
Via Business Wire
FDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer
From CEL-SCI Corporation
Via Business Wire
CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation
From CEL-SCI Corporation
Via Business Wire
CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress
From CEL-SCI Corporation
Via Business Wire
The UK’s Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance
From CEL-SCI Corporation
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.